Toronto, Ontario – (Newsfile Corp. – April 27, 2021) – Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) (“Relay“ose”company“), a shareholder in Glow LifeTech Corp. (CSE: GLOW) (FSE: 9DO) (“glow)), is pleased to provide an update to the news recently distributed by Glow LifeTech Corp.

Glow LifeTech natural health product – ArtemiC

To see an improved version of this graphic, please visit:
https://orders.newsfilecorp.com/files/952/81995_glow.jpg

On April 27, 2021, Glow reported on the submission of an application to Health Canada to obtain manufacturing licenses for the Natural Health Product (NHP), ArtemiC, which reported successful results from a COVID-19 Phase II clinical trial.1

Glow is a biotechnology company focused on producing next-generation, science-backed natural products. ArtemiC ™ was filed with the Canadian Natural and Non-Prescription Health Products Directorate (NNHPD) on March 11, 2021. The application, which is currently being reviewed by Health Canada, included ArtemiC ™, to whom Glow is entitled exclusive in early February.2

“Canada has the potential to set the world stage for COVID-19 natural health products. With Canada Health approval and favorable clinical outcomes, ArtemiC të can become a natural, evidence-based solution to aid patient recovery.” stated Yoav Raiter, CEO, Relay Medical Corp. “Glow has the exclusive rights to market, sell and distribute ArtemiC. In Canada, the United States, Mexico and all Caribbean countries as a food supplement (nutritional, dietary supplement and natural health product).”

For the full and complete update from Glow, please refer to their news release3: https://bit.ly/3eyNqnP

The Company is not making any express or implied claims that it has the ability to eliminate, cure or contain Covid-19 (or SARS-2 Coronavirus) at this time.

About Glow LifeTech Corp
Glow LifeTech is a Canada-based biotechnology company focused on the production of nutraceutical and cannabinoid-based products with improved bio-availability, absorption and effectiveness. Glow is entitled to the innovative plant-based system, the MyCell Technology® supply system, which transforms poorly absorbed natural ingredients into improved water-compatible concentrates that unlock the full healing potential of valuable ingredients.

Website: www.glowlifetech.com

About Relay Medical Corp

Relay Medical is a technology innovator based in Toronto, Ontario with a team of experts focused on developing new technologies in the diagnostics and data sectors of the AI ​​and IoT security sectors.

Website: www.relaymedical.com

For Media Research, please contact: Destine Lee media@relaymedical.com | 647-872-9982

SUBSCRIBE: For more information on Relay or to subscribe to the Company mailing list visit: https://www.relaymedical.com/news

Contact:
W. Clark Kent
President
Relay Medical Corp.
Office. 647-872-9982 shtr. 3
TF 1-844-247-6633 shtr. 3
investitori.relacionet@relaymedical.com

Bernhard Langer
EU investor relations
Office. +49 (0) 177 774 2314
Email: blanger@relaymedical.com

Information Warning Statement looking ahead

With the exception of statements of a historical fact, this press release contains some “forward-looking information” within the meaning of the applicable securities law. The information that looks forward is often characterized by words such as “plan”, “expectation”, “project”, “goal”, “belief”, “forecast”, “evaluation” and other similar words, or statements that event or certain conditions “can” or “will happen”. Forward-looking statements are based on opinions and assessments at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that may cause actual events or outcomes to differ materially from those set out in the forward-looking statements, including: but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are inherent uncertainties in future information, including factors beyond the Company’s control. There is no assurance that the commercialization plans for the technology described in this press release will take effect in the terms or time frame described here. The Company assumes no obligation to update future information if management circumstances or assessments or opinions need to change except as required by law. The reader is warned not to rely unreasonably on future statements. Additional information identifying risks and uncertainties that may affect the financial results is contained in the Company registers with Canadian securities regulators, records of which are available at www.sedar.com.

________________
1 Results of the ArtemiC Full Trial (15 December 2020): https://wcsecure.weblink.com.au/pdf/MXC/02322300.pdf

2 February 16, 2021 kovid-19-phase-ii-clinical trial

3 https://www.newsfilecorp.com/release/81975

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/81995